These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 20360147)
21. Caspase 9 promoter polymorphisms and risk of primary lung cancer. Park JY; Park JM; Jang JS; Choi JE; Kim KM; Cha SI; Kim CH; Kang YM; Lee WK; Kam S; Park RW; Kim IS; Lee JT; Jung TH Hum Mol Genet; 2006 Jun; 15(12):1963-71. PubMed ID: 16687442 [TBL] [Abstract][Full Text] [Related]
22. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Rollin J; Régina S; Vourc'h P; Iochmann S; Bléchet C; Reverdiau P; Gruel Y Lung Cancer; 2007 May; 56(2):273-80. PubMed ID: 17208328 [TBL] [Abstract][Full Text] [Related]
23. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Yu C; Zhou Y; Miao X; Xiong P; Tan W; Lin D Cancer Res; 2004 Oct; 64(20):7622-8. PubMed ID: 15492291 [TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms in MMP 2, 3, 7, and 9 genes and the susceptibility and clinical outcome of cervical cancer in a Chinese Han population. Xie B; Zhang Z; Wang H; Chen Z; Wang Y; Liang H; Yang G; Yang X; Zhang H Tumour Biol; 2016 Apr; 37(4):4883-8. PubMed ID: 26526578 [TBL] [Abstract][Full Text] [Related]
25. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Sharma KL; Misra S; Kumar A; Mittal B Liver Int; 2012 Sep; 32(8):1278-86. PubMed ID: 22621753 [TBL] [Abstract][Full Text] [Related]
26. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects. Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838 [TBL] [Abstract][Full Text] [Related]
27. [Association of polymorphism in matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 with genetic susceptibility of gastric cancer]. Lin XD; Chen G; Li C; Zhang LY; Shi Y; Zhou DM; Zheng XW Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Aug; 45(8):711-6. PubMed ID: 22169692 [TBL] [Abstract][Full Text] [Related]
28. Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer. Jang JS; Lee SJ; Choi JE; Cha SI; Lee EB; Park TI; Kim CH; Lee WK; Kam S; Choi JY; Kang YM; Park RW; Kim IS; Cho YL; Jung TH; Han SB; Park JY Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2474-80. PubMed ID: 16284366 [TBL] [Abstract][Full Text] [Related]
29. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. Tu HF; Wu CH; Kao SY; Liu CJ; Liu TY; Lui MT J Oral Pathol Med; 2007 Aug; 36(7):409-14. PubMed ID: 17617834 [TBL] [Abstract][Full Text] [Related]
30. DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case-control studies. Han S; Zhang HT; Wang Z; Xie Y; Tang R; Mao Y; Li Y Eur J Hum Genet; 2006 Oct; 14(10):1136-44. PubMed ID: 16791138 [TBL] [Abstract][Full Text] [Related]
31. Association of MMP2 and MMP9 gene polymorphisms with the recurrent spontaneous abortion: A meta-analysis. Yan Y; Fang L; Li Y; Yu Y; Li Y; Cheng JC; Sun YP Gene; 2021 Jan; 767():145173. PubMed ID: 33007375 [TBL] [Abstract][Full Text] [Related]
32. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Lei H; Hemminki K; Altieri A; Johansson R; Enquist K; Hallmans G; Lenner P; Försti A Breast Cancer Res Treat; 2007 May; 103(1):61-9. PubMed ID: 17033924 [TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. Benesová Y; Vasků A; Stourac P; Hladíková M; Beránek M; Kadanka Z; Novotná H; Bednarík J J Neuroimmunol; 2008 Dec; 205(1-2):105-9. PubMed ID: 18835646 [TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Wang J; Xu D; Wu X; Zhou C; Wang H; Guo Y; Cao K Heart; 2011 Oct; 97(19):1542-6. PubMed ID: 21900582 [TBL] [Abstract][Full Text] [Related]
35. MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease. Gai X; Zhang Z; Liang Y; Chen Z; Yang X; Hou J; Lan X; Zheng W; Hou J; Huang M Clin Chim Acta; 2010 May; 411(9-10):719-24. PubMed ID: 20138860 [TBL] [Abstract][Full Text] [Related]
36. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer. Tang Y; Zhu J; Chen L; Chen L; Zhang S; Lin J Clin Cancer Res; 2008 May; 14(9):2870-7. PubMed ID: 18451255 [TBL] [Abstract][Full Text] [Related]
37. Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India. Srivastava P; Lone TA; Kapoor R; Mittal RD Arch Med Res; 2012 Feb; 43(2):117-24. PubMed ID: 22374248 [TBL] [Abstract][Full Text] [Related]
38. Potentially functional COX-2-1195G>A polymorphism increases the risk of digestive system cancers: a meta-analysis. Dong J; Dai J; Zhang M; Hu Z; Shen H J Gastroenterol Hepatol; 2010 Jun; 25(6):1042-50. PubMed ID: 20594217 [TBL] [Abstract][Full Text] [Related]
39. Interleukin 1 beta (IL1B) promoter polymorphism and cancer risk: evidence from 47 published studies. He B; Zhang Y; Pan Y; Xu Y; Gu L; Chen L; Wang S Mutagenesis; 2011 Sep; 26(5):637-42. PubMed ID: 21653279 [TBL] [Abstract][Full Text] [Related]
40. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. Liu D; Guo H; Li Y; Xu X; Yang K; Bai Y PLoS One; 2012; 7(2):e31251. PubMed ID: 22348060 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]